Protocol Ledger

NCT04683406 · Phase III · COMPLETED

A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

Interventional Phase III clinical trial protocol NCT04683406 sponsored by Guangdong Raynovent Biotech Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-12-28 Enrollment: 750 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04683406
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)750 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04683406
Protocol FieldVerified Registry Value
NCT IdentifierNCT04683406
Consolidated Lead SponsorGuangdong Raynovent Biotech Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment750 participants (ACTUAL)
Registered Start Date2020-12-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04683406
Hospital Research SiteLocationSite Profile
The First Affiliated Hospital of Bengbu Medical CollegeBengbu, ChinaOpen Hospital Dossier ->
Peking University Third HospitalBeijing, ChinaOpen Hospital Dossier ->
Dongguan People's HospitalDongguan, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI